CXCL13 and cancer: As our understanding of the CXCL13–CXCR5 axis continues to grow, it is becoming clearer that this interacting pair may represent a valuable drug target in multiple disease conditions, including autoimmune disorders and cancers (Airoldi et al., 2008 ▸; Biswas et al., 2014 ▸; Bürkle et al., 2007 ▸; Charbonneau et al., 2013 ▸; El-Haibi et al., 2011 ▸, 2013 ▸; Singh et al., 2009 ▸, 2014 ▸; Dupuis et al., 2006 ▸; Bao et al., 2020 ▸; Klimatcheva et al., 2015 ▸).